Valvular heart disease in patients with Parkinson’s disease treated with pergolide. Course following treatment modifications

Francisco Íñiguez Almech · Journal of Neurology · 2008

Summary

This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.

Type: article
Published: 2008-06-16
Cited by: 15
References: 21
DOI: https://doi.org/10.1007/s00415-008-0839-1
PubMed: https://pubmed.ncbi.nlm.nih.gov/18560792/
OpenAlex: https://openalex.org/W18560792
Semantic Scholar: https://api.semanticscholar.org/CorpusID:6097390

Keywords

Humanities, Art

References

DOPAMINE AGONISTS AND CARDIAC VALVULOPATHY IN PARKINSON DISEASE: A CASE-CONTROL STUDYMitsutoshi Yamamoto, Tadahisa Uesugi, Takeo Nakayama — 2007
Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphineBjörn Tackenberg, Jens Carsten Möller, Karla Eggert — 2006
Dopamine agonists and the risk of cardiac-valve regurgitation.R Schade, Frank Andersohn, Samy Suissa — 2007
Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolideGuy Van Camp, Anja Flamez, Bernard Cosyns — 2003
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.Guy Van Camp, Anja Flamez, Bernard Cosyns — 2004
Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolideEvžen Růžička, Hana Línková, Martin Pěnička — 2007
Valvular heart disease in patients taking pergolide.Allison M. Pritchett, John F. Morrison, William D. Edwards — 2002
Valvular heart disease in patients taking pergolide.E. Andrew Waller, Joseph Kaplan, Michael G. Heckman — 2005
Fibrotic valvular heart disease subsequent to bromocriptine treatment.Jacques Serratrice, P. Disdier, Gilbert Habib — 2002
Pergolide use in Parkinson disease is associated with cardiac valve regurgitationDaniel Baseman, Padraig O’Suilleabhain, Sharon C. Reimold — 2004
Valvular heart disease and the use of dopamine agonists for Parkinson's disease.R Zanettini, Angelo Antonini, Gemma Gatto — 2007
Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonistsJi‐Youn Kim, Eun Joo Chung, Seung Woo Park — 2006
Pericardial, retroperitoneal, and pleural fibrosis induced by pergolideSandip Shaunak, Alastair Wilkins, J B Pilling — 1999
Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.William A. Zoghbi, Maurice Enriquez‐Sarano, Elyse Foster — 2003
Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonistsJudit Horváth, Robin D. Fross, Galit Kleiner‐Fisman — 2004
Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic studyCecilia Peralta, Elisabeth Wolf, Hannes Alber — 2006
The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.Charlene M. Flowers, Judith A. Racoosin, Susan L. Lu — 2003
Dopamine Agonists and the Risk of Cardiac-Valve RegurgitationAditi Verma — 2008
Cardiac Valvulopathy Associated with Pergolide UseCindy Zadikoff, Paula A. Rochon, Anthony E. Lang — 2006
Pergolide use in Parkinson disease is associated with cardiac valve regurgitationUT Southwestern — 2005

Cited by

Role of echocardiography in toxic heart valvulopathy.Steven Droogmans, D. Kerkhove, Bernard Cosyns — 2009
Dose Dependency and Reversibility of Serotonin-Induced Valvular Heart Disease in RatsSteven Droogmans, Bram Roosens, Bernard Cosyns — 2009
Parkinson disease and comorbid cerebrovascular diseaseW. Nanhoe-Mahabier, Karlijn F. de Laat, Jasper E. Visser — 2009
Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.Christophe Tribouilloy, Sylvestre Maréchaux, Y. Jobic — 2013
Current trends in the management of uremic restless legs syndrome: a systematic review on aspects related to quality of life, cardiovascular mortality and survival.Giorgos K. Sakkas, Christoforos D. Giannaki, Christina Karatzaferi — 2015
Drug-induced valvular heart disease: an update.Michel Andréjak, Christophe Tribouilloy — 2013
A long-term echocardiographic study of the course of valvular dysfunctions following discontinuation of ergot-derived dopamine agonists in patients with Parkinson's diseaseWalter Serra, Anna Negrotti, Elena Marchesi — 2015
[Drug-induced valvular heart disease].Daniel N. Blaschke, Sascha Rolf, Abdul Shokor Parwani — 2009
Cardiac Valvulopathy Associated with Pergolide UseCindy Zadikoff, Paula A. Rochon, Anthony E. Lang — 2006
Drug-Associated Valvular Heart Diseases and Serotonin-Related pathways: A Meta-AnalysisJacqueline H. Fortier, Beatrice Pizzarotti, Richard E. Shaw — 2019
Current awareness: Pharmacoepidemiology and drug safety2009
Parkinson’s Disease in Intensive Care UnitL. Velly, D. Boumaza, N. Bruder — 2014
Induction of Valvular Heart Disease by Pharmacological InterventionsS. Droogmans, B. Cosyns — 2015
Chapter 4 – Cardiac disease and pathologyM. Bowen — 2010

Related papers

No related papers recorded.